or Try an Advanced Search...

    Cancer Therapies Stocks List

    Symbol Grade Name % Change
    AVBP C ArriVent BioPharma, Inc. 2.27
    IKNA C Ikena Oncology, Inc. 1.19
    ANL C Adlai Nortye Ltd. -0.34
    GTBP D GT Biopharma, Inc. 4.22
    PSNL D Personalis, Inc. 2.09
    RPTX D Repare Therapeutics Inc. 0.00
    APRE D Aprea Therapeutics, Inc. 5.48
    POAI D Predictive Oncology Inc. -2.79
    SNDX F Syndax Pharmaceuticals, Inc. -1.06
    BYSI F BeyondSpring, Inc. -2.32
    View As Page of Charts
    Related Industries: Biotechnology Medical Instruments & Supplies
    Related Stock Lists: Cancer Biopharmaceutical Biotechnology Antineoplastic Drugs Clinical Medicine Solid Tumors Tumor Biology Cancer Cell Cancer Treatment Genomics Life Sciences Lung Cancer Medicine NSCLC Oncology Pharmaceutical Precision Medicine Acute Myeloid Leukemia Advanced Non Small Cell Lung Cancer

    Related ETFs - A few ETFs which own one or more of the above listed Cancer Therapies stocks.

    Symbol Grade Name Weight
    ARKG F ARK Genomic Revolution Multi-Sector ETF 3.34
    CNCR F Loncar Cancer Immunotherapy ETF 2.91
    SURI C Simplify Exchange Traded Funds Simplify Propel Opportunities ETF 1.47
    SBIO C ALPS Medical Breakthroughs ETF 1.13
    BBC D Virtus LifeSci Biotech Clinical Trials ETF 0.66
    View all Cancer Therapies ETFs...
    Compare ETFs
    Compare ARKG to BBC Compare ARKG to CNCR Compare ARKG to SURI

        Cancer Therapies Stocks Recent News

        Date Stock Title
        Nov 18 SNDX Syndax secures FDA OK for new kind of leukemia drug
        Nov 18 SNDX FDA approves Syndax’s Revuforj to treat leukaemia
        Nov 15 SNDX Syndax wins FDA approval for leukemia drug revumenib
        Nov 15 SNDX Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
        Nov 15 POAI Predictive Oncology Third Quarter 2024 Earnings: Misses Expectations
        Nov 15 GTBP GT Biopharma GAAP EPS of -$1.53
        Nov 15 AVBP ArriVent BioPharma GAAP EPS of -$0.61 beats by $0.11
        Nov 14 GTBP GT Biopharma Reports Third Quarter 2024 Financial Results
        Nov 14 SNDX Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data
        Nov 14 AVBP ArriVent BioPharma Reports Third Quarter 2024 Financial Results
        Nov 13 SNDX Syndax’s stock sinks by 25% despite AML trial meeting primary endpoint
        Nov 13 APRE Here's Why Aprea Therapeutics (APRE) Could be Great Choice for a Bottom Fisher
        Nov 13 IKNA 3 US Penny Stocks With Market Caps Over $40M To Consider
        Nov 13 POAI Predictive Oncology GAAP EPS of -$0.36 misses by $0.10, revenue of $0.35M in-line
        Nov 13 SNDX Syndax’s revumenib meets primary results in AML trial
        Nov 13 POAI Predictive Oncology Reports Third Quarter 2024 Financial Results and Provides Strategic Update
        Nov 13 RPTX Industry Analysts Just Made A Notable Upgrade To Their Repare Therapeutics Inc. (NASDAQ:RPTX) Revenue Forecasts
        Nov 12 SNDX Syndax: Fall On NPM1m AML Data Of Revumenib Creates Buy Opportunity
        Nov 12 SNDX Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer
        Related Industries: Biotechnology Medical Instruments & Supplies
        Related Stock Lists: Cancer Biopharmaceutical Biotechnology Antineoplastic Drugs Clinical Medicine Solid Tumors Tumor Biology Cancer Cell Cancer Treatment Genomics Life Sciences Lung Cancer Medicine NSCLC Oncology Pharmaceutical Precision Medicine Acute Myeloid Leukemia Advanced Non Small Cell Lung Cancer
        Cancer Therapies

        Cancer therapies are treatments used to destroy or control cancer cells. These therapies can include surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapy. Depending on the type and stage of cancer, a combination of therapies may be used.

        Browse All Tags